Focused On-demand Library for Probable E3 ubiquitin-protein ligase MARCHF10

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8NA82

UPID:

MARHA_HUMAN

Alternative names:

Membrane-associated RING finger protein 10; Membrane-associated RING-CH protein X; RING finger protein 190; RING-type E3 ubiquitin transferase MARCHF10

Alternative UPACC:

Q8NA82; D3DU09; Q8IYS7; Q8N7Z7

Background:

The Probable E3 ubiquitin-protein ligase MARCHF10, identified by the accession number Q8NA82, plays a pivotal role in the ubiquitin-proteasome system. This enzyme, also known as Membrane-associated RING finger protein 10, Membrane-associated RING-CH protein X, RING finger protein 190, and RING-type E3 ubiquitin transferase MARCHF10, is instrumental in transferring ubiquitin from an E2 ubiquitin-conjugating enzyme to targeted substrates. Its activity is crucial for the regulation of protein turnover, impacting various cellular processes.

Therapeutic significance:

Understanding the role of Probable E3 ubiquitin-protein ligase MARCHF10 could open doors to potential therapeutic strategies.